A phase I study of nedaplatin, pemetrexed and thoracic intensity-modulated radiotherapy for inoperable stage III lung adenocarcinoma

Table 4 Efficacy (RECIST version 1.1)

Study phase	Response	N	%
Chemoradiation	CR	0	0.0
	PR	13	86.7
	SD	2	13.3
	PD	0	0.0
Treatment completion	CR	1	6.7
	PR	11	73.3
	SD	3	20.0
	PD	0	0

CR complete response, PR partial response, SD stable disease, PD progressive disease

ISSN: 1471-2407